Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment
NCT ID: NCT01205477
Last Updated: 2010-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
58 participants
INTERVENTIONAL
2009-09-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methylprednisolone
Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
EXPERIMENTAL
Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Placebo
Infiltration of 1 mL of xylocaine
PLACEBO
Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EXPERIMENTAL
Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
PLACEBO
Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Autonoma de Nuevo Leon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Departamento de Reumatología, Hospital Universitario "José Eleuterio González" de la Universidad Autónoma de Nuevo León
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mario Alberto Garza Elizondo, MD
Role: STUDY_DIRECTOR
Universidad Autónoma de Nuevo León
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario "José Eleuterio González"
Monterrey, Nuevo León, Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Alvarez-Nemegyei J, Canoso JJ. Evidence-Based Soft Tissue Rheumatology IV: Anserine Bursitis. J Clin Rheumatol. 2004 Aug;10(4):205-6. doi: 10.1097/01.rhu.0000135561.41660.b0.
Calvo-Alén J, Rua-Figueroa I, Erausquin C. Anserine bursitis treatment: local corticoesteroid injction against NSAID: a prospective study [Spanish]. Rev Esp Reumatol. 1993;20:13-15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RE09-009
Identifier Type: -
Identifier Source: org_study_id